BOSTON, Nov. 22 /PRNewswire/ -- Evidence Medical, a Delaware limited liability company, and Advanced Biological Laboratories (http://www.ablsa.com/, Luxembourg resident company) have announced an exclusive license agreement in which Evidence Medical acquired exclusive rights to ABL's 'decision support' patents in exchange for cash and a limited license back to ABL. Financial and other terms were not disclosed.
Gary Paul Magnant, Evidence Medical's President, expressed the importance of the patents to the future of the company. "Control of these patents was at the heart of our business strategy," said Magnant. "We believe the patents will prove seminal to the diagnosis and treatment of most chronic diseases. The patents broadly cover the computer analysis of multiple databases which lead to a report meant to guide physicians towards the optimal therapy for a given patient. Historically, such reports were principally associated with the treatment of HIV, but we envision that eventually the diagnosis and treatment of most chronic diseases will fall under the claims of these patents as well. We intend to widely license the patents to diagnostic companies, diagnostic service providers and therapeutic manufacturers."
Arsene Kronshagen, Chairman of the Board of Directors of ABL concurred with Magnant and added, "Based on the experience of Evidence Medical's founders, we expect Evidence Medical will be a great partner for ABL. Evidence Medical is now positioned to build a strong network of licensees, including leading diagnostic, therapeutic and clinical reference laboratory companies. Using ABL's artificial intelligence based technology, the clinical and diagnostic decision support and database software products are already being commercialized. The relationship with Evidence Medical will help us to engage ABL as a worldwide leader in the growing and strategic business of providing evidence-based tools to support physicians in the decisions they face in treating complex diseases with a plethora of interacting and expensive therapeutics."
About Evidence Medical:
Evidence Medical holds exclusive license to certain US patents (US6,081,786 and US6,188,988) and their foreign equivalents. Evidence Medical is in the business of licensing key strategic intellectual properties to diagnostic manufacturers, pharmaceutical companies, and diagnostic service providers. For more information, visit Evidence Medical's website at http://www.evidencemedical.com/.
About ABL SA:
Advanced Biological Laboratories (ABL) S.A. is a biotech company that was created in 2000 as a spin-off from the European academic research center (CRP- Sante, Luxembourg). ABL's expertise is in infectious diseases and more specifically in the molecular biology and clinical outcome predictors of HIV, hepatitis and HPV viruses. The company has developed a strong focus on HIV drug resistance, algorithm-based genotype interpretation systems, clinical decision support systems and the management of sequence and complex integrated clinical and virological databases. ABL offers a complete line of products to support clinical and diagnostic companies in the complex tasks of managing this data and using it to support improved clinical outcomes. ABL participates in several research and development projects including the provision of the ViroScore resistance interpretation and sequence management system for the EU-sponsored research project called SPREAD (Strategy to Control Spread of HIV Drug Resistance). ABL has commercialized the ViroScore Suite and the TherapyEdge-HIV decision support and patient management system and has broad experience applying these data-warehousing solutions on a country-level and continent-wide basis. For more information on ABL products and services visit the corporate website at http://www.ablsa.com/.
Contact: Gary Magnant, Evidence Medical, LLC, info@evidencemedical.com
Advanced Biological Laboratories, SA, info@ablsa.com
Evidence Medical, LLCCONTACT: Gary Magnant of Evidence Medical, LLC,info@evidencemedical.com; or Advanced Biological Laboratories, SA,info@ablsa.com
